(NASDAQ: CLNN) Clene's forecast annual revenue growth rate of 103.75% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Clene's revenue in 2024 is $654,000.On average, 2 Wall Street analysts forecast CLNN's revenue for 2024 to be $84,763,865, with the lowest CLNN revenue forecast at $77,058,059, and the highest CLNN revenue forecast at $92,469,671. On average, 2 Wall Street analysts forecast CLNN's revenue for 2025 to be $70,636,554, with the lowest CLNN revenue forecast at $64,215,049, and the highest CLNN revenue forecast at $77,058,059.
In 2026, CLNN is forecast to generate $841,217,142 in revenue, with the lowest revenue forecast at $64,215,049 and the highest revenue forecast at $1,618,219,235.